drugset / Trial / NCT05126004

AZA Combined With NAC for PIT After HSCT

NCT05126004

RandomizedParallel-groupTriple-blindTreatment

Summary

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.

Timeline

Start
2021-12-01
Primary completion
2024-06-30
Completion
2026-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 50 mg Subcutaneous
Subject N-acetylcysteine Small molecule 600 mg Oral